ESPR News

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Esperion to Participate in Jefferies Global Healthcare Conference - London

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

Esperion Announces Pricing of Public Offering of Common Stock